Nanosphere (NASDAQ:NSPH)

Multiple choice question:

The name "Nanosphere" refers to which of the following?

A) The company's patented gold nanoparticle probe technology.

B) The size of the company's revenues versus their competitors.

C) The tiny little zero one arrives at when calculating this company's odds of long-term survival.

D) B and C

Speculative play, but looks like very good upside potential not much downside.

A director just bought 285,000 shares, or $459,201 worth of stock, at $1.57 to $1.64 per share. This same director also bought 2,700,000 shares, or $5.94 million worth of stock, at $2.20 back on May 10.

Just a min after the kind BravoBevo it's good, but I prefer to be first like for ACUR...
However the most difficut is to know the right time for selling...

Rapid diagnostics are going to be the next big thing.

It's good,I like it

Well positioned in an industry that is poised for a dramatic acceleration in growth as predictive medicine and molecular diagnostics begin to gain traction. Recent weakness primarily driven by shorter term concerns present a great entry point for longer term investors. While still burning cash (although moderatimg), a solid cash position (over $2 per share in net cash) provides sufficient financial flexibility. A good insider rating (recent CEO and 30% owner buys with no sells) is also encouraging.

Picked this on a whim.... looks like it's doing alright :)

I do TNT testing where I work and if approved by the FDA this assay will mean serious $$$ for this company seeing as it is an extremely important test indicating the occurrence of several different heart disorders, including myocardial infarction. Thus, this is an extremely critical test and must be completed ASAP.

I'd call this a speculative buy at this point with great potential and a tremendous growth opportunity. If the FDA approves the next 4 tests in their pipeline this company will be a definite buy.

Note: Healthcare is virtually untouchable no matter what the state of the economy, especially diagnostics which hospitals cannot live without.

Disclosure: I am also putting my money where my mouth is as I own this in my real portfolio with my sight on the long-long-term.

Love the technology. Risks = they are thinly traded and very volatile.

Increased demand for DNA analysis,

This company is doing really cool things and think it would change our lives if it became the market leader in the emerging field of genetic and nano testing.

25,000

these kind of companies usually tend to work better on a long the range as it takes time to develope new items.

Interesting bio-tech company in the nano-technology field.

Useful nanotech.

joseph714 @ 11.93

new issue great products will take off after new analyst ratings come out very strong buy

see:

http://www.hoovers.com/nanosphere/--ID__131243--/free-co-factsheet.xhtml